Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury

Nature Communications

Volumn 6, Issue , 2015, Pages

  Ito, Minako ^a,b   Shichita, Takashi ^a,b   Okada, Masahiro ^a,b   Komine, Ritsuko ^a,b   Noguchi, Yoshiko ^a,b   Yoshimura, Akihiko ^a,b   Morita, Rimpei ^a,b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; CRYOPYRIN; IBRUTINIB; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; AGAMMAGLOBULINAEMIA TYROSINE KINASE; CARRIER PROTEIN; NLRP3 PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

APOPTOSIS; BRAIN; DRUG; ENZYME ACTIVITY; HORMONE; INHIBITION; INJURY; MATURATION; PROTEIN; RODENT; SECRETION; STROKE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL ACTIVATION; DRUG MECHANISM; DRUG TARGETING; ENZYME INACTIVATION; MACROPHAGE; MOUSE; NEUROPROTECTION; NEUTROPHIL; NONHUMAN; OLIGOMERIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

MUS;

ANIMALS; BRAIN ISCHEMIA; CARRIER PROTEINS; INFLAMMASOMES; MICE; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84931287986     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8360     Document Type: Article

References (61)

1. Moskowitz, M. A., Lo, E. H. & Iadecola, C. The science of stroke: mechanisms in search of treatments. Neuron 67, 181-198 (2010).
2. Eltzschig, H. K. & Eckle, T. Ischemia and reperfusion-from mechanism to translation. Nat. Med. 17, 1391-1401 (2011).
3. Iadecola, C. & Anrather, J. The immunology of stroke: from mechanisms to translation. Nat. Med. 17, 796-808 (2011).
4. Shichita, T. et al. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat. Med. 15, 946-950 (2009).
5. Shichita, T., Sakaguchi, R., Suzuki, M. & Yoshimura, A. Post-ischemic inflammation in the brain. Front. Immunol. 3, 132 (2012).
6. Clarkson, B. D. et al. T cell-derived interleukin (IL)-21 promotes brain injury following stroke in mice. J. Exp. Med. 211, 595-604 (2014).
7. Shichita, T., Ito, M. & Yoshimura, A. Post-ischemic inflammation regulates neural damage and protection. Front. Cell Neurosci. 8, 319 (2014).
8. Keller, M., Ruegg, A., Werner, S. & Beer, H. D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 132, 818-831 (2008).
9. Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821-832 (2010).
10. Williams, A., Flavell, R. A. & Eisenbarth, S. C. The role of NOD-like receptors in shaping adaptive immunity. Curr. Opin. Immunol. 22, 34-40 (2010).
11. Strowig, T., Henao-Mejia, J., Elinav, E. & Flavell, R. Inflammasomes in health and disease. Nature 481, 278-286 (2012).
12. Boutin, H. et al. Role of IL-1alpha and IL-1beta in ischemic brain damage. J. Neurosci. 21, 5528-5534 (2001).
13. Schielke, G. P., Yang, G. Y., Shivers, B. D. & Betz, A. L. Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. J. Cereb. Blood Flow Metab. 18, 180-185 (1998).
14. Yang, F. et al. NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke. J. Cereb. Blood Flow Metab. 34, 660-667 (2014).
15. Olsson, S. et al. Genetic variation within the interleukin-1 gene cluster and ischemic stroke. Stroke 43, 2278-2282 (2012).
16. Bauernfeind, F. G. et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183, 787-791 (2009).
17. Bauernfeind, F. et al. Inflammasomes: current understanding and open questions. Cell. Mol. Life Sci. 68, 765-783 (2011).
18. Ito, M., Yanagi, Y. & Ichinohe, T. Encephalomyocarditis virus viroporin 2B activates NLRP3 inflammasome. PLoS Pathog. 8, e1002857 (2012).
19. Eisenbarth, S. C., Colegio, O. R., O'Connor, W., Sutterwala, F. S. & Flavell, R. A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122-1126 (2008).
20. Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847-856 (2008).
21. Lu, B. et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488, 670-674 (2012).
22. Qu, Y. et al. Phosphorylation of NLRC4 is critical for inflammasome activation. Nature 490, 539-542 (2012).
23. Chuang, Y. T. et al. Tumor suppressor death-associated protein kinase is required for full IL-1beta production. Blood 117, 960-970 (2011).
24. Lin, K. M. et al. IRAK-1 bypasses priming and directly links TLRs to rapid NLRP3 inflammasome activation. Proc. Natl Acad. Si. USA 111, 775-780 (2014).
25. Gross, O. et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 459, 433-436 (2009).
26. Okada, M., Matsuzawa, A., Yoshimura, A. & Ichijo, H. Lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation. J. Biol. Chem. 289, 32926-32936 (2014).
27. Hara, H. et al. Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat. Immunol. 14, 1247-1255 (2013).
28. Jefferies, C. A. et al. Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J. Biol. Chem. 278, 26258-26264 (2003).
29. Lee, K. G. et al. Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response. Proc. Natl Acad. Sci. USA 109, 5791-5796 (2012).
30. Jefferies, C. A. & O'Neill, L. A. Bruton's tyrosine kinase (Btk)-the critical tyrosine kinase in LPS signalling? Immunol. Lett. 92, 15-22 (2004).
31. Mohamed, A. J. et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol. Rev. 228, 58-73 (2009).
32. Mohamed, A. J., Nore, B. F., Christensson, B. & Smith, C. I. Signalling of Bruton's tyrosine kinase, Btk. Scand. J. Immunol. 49, 113-118 (1999).
33. Herrera, A. F. & Jacobsen, E. D. Ibrutinib for the treatment of mantle cell lymphoma. Clin. Cancer Res. 20, 5365-5371 (2014).
34. Mangla, A. et al. Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood 104, 1191-1197 (2004).
35. van de Veerdonk, F. L. et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 63, 1507-1516 (2011).
36. Chang, B. Y. et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res. Ther. 13, R115 (2011).
37. Vargas, L., Hamasy, A., Nore, B. F. & Smith, C. I. Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. Scand. J. Immunol. 78, 130-139 (2013).
38. Thomas, J. D. et al. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 261, 355-358 (1993).
39. Fernandes-Alnemri, T. et al. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat. Immunol. 11, 385-393 (2010).
40. Freigang, S. et al. Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1alpha and sterile vascular inflammation in atherosclerosis. Nat. Immunol. 14, 1045-1053 (2013).
41. Zhang, W. H. et al. Fundamental role of the Rip2/caspase-1 pathway in hypoxia and ischemia-induced neuronal cell death. Proc. Natl Acad. Sci. USA 100, 16012-16017 (2003).
42. Ross, J., Brough, D., Gibson, R. M., Loddick, S. A. & Rothwell, N. J. A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat. Neuropharmacology 53, 638-642 (2007).
43. Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075-13080 (2010).
44. Mankan, A. K., Dau, T., Jenne, D. & Hornung, V. The NLRP3/ASC/Caspase-1 axis regulates IL-1beta processing in neutrophils. Eur. J. Immunol. 42, 710-715 (2012).
45. Neumann, K. & Ruland, J. Kinases conquer the inflammasomes. Nat. Immunol. 14, 1207-1208 (2013).
46. Hasegawa, E. et al. IL-23-independent induction of IL-17 from gammadeltaT cells and innate lymphoid cells promotes experimental intraocular neovascularization. J. Immunol. 190, 1778-1787 (2013).
47. Sutton, C. E. et al. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31, 331-341 (2009).
48. Shichita, T. et al. Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat. Med. 18, 911-917 (2012).
49. Hedtjarn, M., Mallard, C. & Hagberg, H. Inflammatory gene profiling in the developing mouse brain after hypoxia-ischemia. J. Cereb. Blood Flow Metab. 24, 1333-1351 (2004).
50. Chen, Y. et al. Intrastriatal B-cell administration limits infarct size after stroke in B-cell deficient mice. Metab. Brain Dis. 27, 487-493 (2012).
51. Dinarello, C. A. Interleukin-1beta and the autoinflammatory diseases. N. Engl. J. Med. 360, 2467-2470 (2009).
52. Singhal, G., Jaehne, E. J., Corrigan, F., Toben, C. & Baune, B. T. Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front. Neurosci. 8, 315 (2014).
53. Dinarello, C. A. & van der Meer, J. W. Treating inflammation by blocking interleukin-1 in humans. Semin. Immunol. 25, 469-484 (2013).
54. Akinleye, A., Chen, Y., Mukhi, N., Song, Y. & Liu, D. Ibrutinib and novel BTK inhibitors in clinical development. J. Hematol. Oncol. 6, 59 (2013).
55. Horai, R. et al. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187, 1463-1475 (1998).
56. Koga, K. et al. Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity 30, 372-383 (2009).
57. Morita, R. et al. ETS transcription factor ETV2 directly converts human fibroblasts into functional endothelial cells. Proc. Natl Acad. Sci. USA 112, 160-165 (2015).
58. Heinonen, J. E., Smith, C. I. & Nore, B. F. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett. 527, 274-278 (2002).
59. Shenoy, A. R. et al. GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. Science 336, 481-485 (2012).
60. Bederson, J. B. et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17, 472-476 (1986).
61. Tamiya, T. et al. Smad2/3 and IRF4 play a cooperative role in IL-9-producing T cell induction. J. Immunol. 191, 2360-2371 (2013).